Alzheimer's disease: Relationship between muscarinic cholinergic receptors, β-amyloid and tau proteins

Fundamental and Clinical Pharmacology

Volumn 12, Issue 5, 1998, Pages 473-481

  Pavia J ^a   De Ceballos, Ml ^b   Sanchez De La Cuesta, F ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b INSTITUTO CAJAL   (Spain)

Author keywords

Alzheimer's disease; Muscarinic receptors; Tau; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL TRISPHOSPHATE; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR; PHOSPHATIDYLINOSITIDE; TAU PROTEIN;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; DISEASE ASSOCIATION; ENZYME SYNTHESIS; HUMAN; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RECEPTOR AFFINITY; RECEPTOR DENSITY; REVIEW; SECOND MESSENGER; SENILE DEMENTIA;

EID: 0032426901     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1998.tb00975.x     Document Type: Review

References (99)

1. Adem A, Nordberg A, Bucht G, Winbland B. Extraneural cholinergic markers in Alzheimer's and Parkinson's diseases. Prog Neuropsychopharmacol Biol Psychiat 1986 ; 10 : 247-57
2. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psichiatr 1907 ; 64 : 146-8
3. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 1988 ; 50 : 1914-23
4. Auld DS, Kar S, Quirion R. β-Amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci 1998 ; 21 : 43-9
5. Bartus RT, Dean RLI, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982 ; 217 : 408-17
6. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994 ; 77 : 817-27
7. Berger-Sweenwy J, Heckers S, Mesulam MM, Wiley RG, Lappi DA, Sharma M. Differential effects on spatial navigation of immunotoxin-induced cholinergic lesions of the medial septal area and nucleus basalis magnocellularis. J Neurosci 1994 ; 14 : 4507-19
8. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995 ; 64 : 749-60
9. Blokland A. Acetylcholine: a neurotransmitter for learning and memory? Brain Res Rev 1996 ; 21 : 285-300
10. Bothmer J, Markerink M, Jolles J. Evidence for a selective decrease in type 1 phosphatidylinositol kinase activity in brains of patients with Alzheimer's disease. Dementia 1994 ; 5 : 6-11
11. Brann MR, Ellis J, Jorgensen H, Hill-Eubanks D, Jones SP. Muscarinic acetylcholine receptor subtypes: localization and structure/function. In: Cuello A.C., ed. Progress in Brain Research. Amsterdam: Elsevier Science Publishers; 1993. pp. 121-7
12. Breteler MMB, Claus JJ, Van Duijn CM, Launer LJ, Hofman A. Epidemiology of Alzheimer's disease. Epidemiol Rev 1992 ; 14 : 59-82
13. Busciglio J, Lorenzo A, Yeh J, Yanker BA. β-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995 ; 14 : 879-88
14. Butcher LL, Wolf NJ. Cholinergic system in the central nervous system: retrospection, anatomic distribution and functions. In: Hanin I, ed. Dynamics of cholinergic function. New York: Plenum Press; 1986. pp. 1-11
15. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992 ; 89 : 10075-8
16. Cacabelos R, Caamaño J, Alvarez XA, Fernandez-Novoa L, Franco A. Enfermedad de Alzheimer. Bases moleculares, criterios diagnosticos y normativa terapéutica. Jano 1994 ; 47 : 39-64
17. Callahan MJ, Kinsora JJ, Harbaugh RE, Reeder TM, Davis RE. Continuous ICV infusion of scopolamine impairs sustained attention of rhesus monkeys. Neurobiol Aging 1993 ; 14 : 147-51
18. 3H]MK-801 binding to rat cortical membranes in the presence of glutamate and glycine. J Neurochem 1993 ; 60 : 2296-303
19. Candy JM, Fairbairn AF, Johnson M, Perry EK, Perry RH, Smith C. Hippocampal cholinergic (muscarinic, and putative nicotinic) receptors in human cognitive disorders. Br J Pharmacol 1986 ; 88 : 359P
20. Coyle JT, Price DL, De Long MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983 ; 219 : 1184-90
21. Davies P, Verth AH. Regional distribution of muscarinic acetylcholine receptors in normal and Alzheimer's type dementia brains. Brain Res 1978 ; 138 : 385-92
22. De Figueiredo JM. Epidemiology of Alzheimer's disease: Research trends in the United States. Inter J Geriat Psychiat 1993 ; 8 : 59-65
23. Dei S, Bellucci C, Ghelardini C, Romanelli MN, Spampinato S. Synthesis, characterization and pharmacological profile of tropicamide enantiomers. Life Sci 1996 ; 58 : 2147-53
24. Dekker AJAM, Connor DJ, Thai LJ. The role of cholinergic projections from the nucleus basalis in memory. Neurosci Biobehav Revs 1991 ; 15 : 299-317
25. Drachman DA, Leavitt JL. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974 ; 30 : 113-21
26. Everitt BJ, Robbins TW. Central cholinergic system and cognition. Annu Rev Psychol 1997 ; 48 : 649-84
27. Fernando JC, Abdallah EA, Evinger M, Forray C, El-Fakahany EE. The presence of an M4 subtype muscarinic receptor in the bovine adrenal medulla revealed by mRNA and receptor binding analyses. Eur J Pharmacol 1991 ; 207 : 297-303
28. Fibiger HC. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trend Neurosci 1991 ; 14 : 220-3
29. 1 muscarinic receptor in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann Neurol 1991 ; 29 : 256-62
30. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995 ; 64 : 1888-91
31. 4 binding in Alzheimer's disease brain. Brain Res 1995 ; 681 : 160-6
32. Giovannelli L, Casamenti F, Scali L, Bartolini L, Pepeu G. Differential effects of amyloid peptides β-(1-40) and β-(25-35) injections into the rat nucleus basalis. Neuroscience 1995 ; 66 : 781-92
33. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987 ; 235 : 877-80
34. Goyal RK. Muscarinic receptor subtypes: physiology and clinical implications. New Eng J Med 1989 ; 321(15) : 1022-5
35. Greenwood AF, Powers RE, Jope RS. Phosphoinositide hydrolysis, Gαq, phospholipase C, and protein kinase C in post mortem human brain: Effects of post mortem interval, subject age, and Alzheimer's disease. Neuroscience 1995 ; 69 : 125-38
36. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992 ; 359 : 322-5
37. 2 receptor G-protein interactions in the neocortex of patients with Alzheimer's disease. Neurosci Lett 1995 ; 186 : 57-60
38. Hoshi M, Takashima A, Murayama M, Yasutake K, Yoshida N, Ishiguro K, Hoshino T, Imahori K. Nontoxic amyloid beta peptide 1-42 suppresses acetylcholine synthesis: possible role in cholinergic dysfunction in Alzheimer's disease. J Biol Chem 1997 ; 272: 2038-41
39. Hulme EC, Birdsall NJM, Buckley NJ. Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol 1990 ; 30 : 633-73
40. Itoh A, Nitta A, Nadai M, Nishimura K, Hirose M, Hasegawa T, Nabeshima T. Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein-infused rats. J Neurochem 1996 ; 66 : 1113-7
41. Jonson GVW, Jenkins SM. Tau protein in normal and Alzheimer's disease brain. Alzheimer's Disease Rev 1996 ; 1 : 38-54
42. 3H]PtdInS hydrolysis in postmortem human brain membranes is mediated by the G-proteins Gq/11 and phospholipase C-β. Biochem J 1994 ; 304 : 655-9
43. Jope RS, Song L, Li X, Powers R. Impaired phosphoinositide hydrolysis in Alzheimer's disease brain. Neurobiol Aging 1994 ; 15 : 221-6
44. Jope RS. Cholinergic muscarinic receptor signalling by the phosphoinositide signal transduction system in Alzheimer's disease. Alzheimer's Disease Rev 1996 ; 1 : 2-14
45. Jope RS, Song L, Power RE. Cholinergic activation of phosphoinositide signalling is impaired in Alzheimer's disease brain. Neurobiol Aging 1997 ; 18 : 111-20
46. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987 ; 325 : 733-6
47. Kar S, Seto D, Gaudreau P, Quirion R. Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J Neurosci 1996 ; 16 : 1034-40
48. Katzman R. Alzheimer's disease. New Eng J Med 1986 ; 314 : 964-73
49. Kellar KJ, Whitehouse PJ, Martino-Barrows AM, Marcus K, Price DL. Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex. Brain Res 1987 ; 436 : 62-8
50. Kelly JF, Furukawa K, Barger SW, Rengen MR, Mark RJ, Blanc EM, Roth GS, Mattson MP. Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc Natl Acad Sci USA 1996 ; 93 : 6753-8
51. Krnjevic K. Central cholinergic mechanisms and function. Prog Brain Res 1993 ; 98 : 285-92
52. Lang W, Henke H. Cholinergic receptor binding and autoradiography in brains of non-neurological and senile dementia of Alzheimer-type patients. Brain Res 1983 ; 267 : 278-80
53. Lawrence AD, Sahakian BJ. Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord 1995 ; 9 (suppl 2) : 43-9
54. Lazareno S, Buckley NJ, Roberts FF. Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells. Mol Pharmacol 1990 ; 38 : 805-15
55. Leanza G, Nilsson OG, Nikkhah G, Wiley RG. Björklund A. Effects of neonatal lesions of the basal forebrain cholinergic system by 192 immunoglobulin G-saporin: biochemical, behavioral and morphological characterization. Neuroscience 1996 ; 74 : 119-41
56. Ledesma MD, Avila J, Correas I. Isolation of a phosphorilated soluble tau fraction from Alzheimer's disease brain. Neurobiol Aging 1995 ; 16 : 515-22
57. Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer's Disease. Proc Natl Acad Sci USA 1996 ; 93 : 13541-6
58. London ED, Waller SB. Relation-ship between choline acetyltransferase and muscarinic binding in aging rodent brain and Alzheimer's disease. In: Hanin I, ed. Dynamics of Cholinergic Function. New York: Plenum Press; 1986. pp. 215-24
59. 2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985 ; 228 : 1115-7
60. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. β-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992 ; 12 : 367-89
61. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein. Neuron 1993 ; 10 : 243-54
62. Mattson MP. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997 ; 77 : 1081-132
63. McGeer PL, McGeer EG, Kimura H, Peng JF. Cholinergic neurons and cholinergic projections in the mammalian C.N.S. In: Hanin I, ed. Dynamics of Cholinergic Function. New York: Plenum Press; 1986. pp. 11-22
64. McKinney M. Muscarinic receptor subtype-specific coupling to second messengers in neuronal systems. Prog Brain Res 1993 ; 98 : 330-40
65. Muir JL, Everitt BJ, Robbins TW. AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function. J Neurosci 1994 ; 14 : 2312-26
66. 3 receptor antagonist, ondasetron. Psychopharmacology 1995 ; 118 : 82-92
67. Nilsson OG, Leanza G, Rosenblad C, Lappi DA, Wiley RG, Bjorklund A. Spatial learning impairments in rats with selective immunolesion of the forebrain cholinergic system. Neuroreport 1992 ; 3 : 1005-8
68. Nitsch RM, Slack BE, Wurtman RJ, Gordon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992 ; 258 : 304-7
69. Nitsch RM, Wurtman RJ, Growdon JH. Regulation of APP processing: potential for the therapeutical reduction of brain amyloid burden. Ann N Y Acad Sci 1996 ; 777 : 175-82
70. Palacios JM. Autoradiographic localization of muscarinic cholinergic receptors in the hippocampus of patients with senile dementia. Brain Res 1982 ; 243 : 173-5
71. Pavía J, De Ceballos ML, Sanchez de la Cuesta F. Muscarinic receptors in Alzheimer's disease. Meth Find Exp Clin Pharmacol 1996 ; 18 (suppl B) : 71-5
72. Perez JM. Alois Alzheimer. Jano 1994 ; 47 : 57-61
73. Perry EK, Perry RH, Blessedd G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977 ; 1 : 189
74. 3H]acetylcholine release from rat hippocampal slices. J Pharmacol Exp Ther 1988 ; 244 : 213-7
75. Price DL. New perspectives in Alzheimer's disease. Ann Rev Neurosci 1986 ; 9 : 489-512
76. Probst A, Cortes R, Ulrich J, Palacios JM. Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer's disease: an autoradiographic study. Brain Res 1988 ; 450 : 190-201
77. Raiteri M, Leardi R, Marchi M. Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. J Pharmacol Exp Ther 1984 ; 228 : 209-14
78. 2 'cardiac' muscarinic receptors. Eur J Pharmacol 1990 ; 177 : 181-7
79. Reisine TD, Yamamura HI, Bird ED, Spokes E, Enna SJ. Pre- and post-synaptic neurochemical alterations in Alzheimer's disease. Brain Res 1978 ; 159 : 477-80
80. Rinne JO, Laakso K, Lonnberg P, Molsa P, Paljarvi L, Rinne JK, Sako E, Rinne UK. Brain muscarinic receptors in senile dementia. Brain Res 1985 ; 336 : 19-25
81. 4 muscarinic receptor subtypes in Alzheimer's disease. Synapse 1997 ; 26 : 341-50
82. Ross BM. Signal sorting and amplification through G-protein coupled receptors. Neuron 1989 ; 3 : 141-52
83. 1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 1996 ; 66 : 877-80
84. Selkoe DJ. Biochemistry of altered brain proteins in Alzheimer's disease. Ann Rev Neurosci 1989 ; 12 : 463-90
85. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Ann Rev Neurosci 1994 ; 17 : 489-517
86. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992 ; 359 : 325-7
87. 3 muscarinic acetylcholine receptor. J Biol Chem 1995 ; 270 : 8337-44
88. Smith CJ, Perry EK, Perry RH, Candy JM, Jhonson M, Bonham JR, Dick DJ, Fairbairn A, Blessed G, Birdsall NJM. Muscarinic cholinergic receptor subtypes in hippocampus in human cognitive disorders. J Neurochem 1988 ; 50 : 847-56
89. 3H-oxotremorine-M binding in normal and Alzheimer's disease parietal cortex: an index of muscarinic receptor-G-protein coupling. Biochem Soc Trans 1989; 17 : 202-3
90. Steckler T, Keith AB, Wiley RG, Sahgal A. Cholinergic lesions by 192 IgG-saporin and short-term recognition memory: Role of the septohippocampal projection. Neuroscience 1995 ; 66 : 101-14
91. Svensson AL, Warpman U, Hellstrom-Lindahl E, Bogdanovic N, Lannfelt L, Nordberg A. Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Neurosci Lett 1997 ; 232 : 37-40
92. Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, Ishiguro K, Imahori K. Exposure of rat hippocampal neurons to amyloid β peptide (25-35) induces the activation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I glycogen synthase kinase-3β. Neurosci Lett 1996 ; 203 : 33-6
93. Torres EM, Perry TA, Blokland A, Wilkinson LS, Wiley RG, Lappi DA, Dunnett SB. Behavioral, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system. Neuroscience 1994 ; 63 : 95-122
94. Toselli N, Lang J, Coeta T, Lux HD. Direct modulation of voltage-dependent calcium channels by muscarinic activation of a pertussis toxin-sensitive G-protein in hippocampal neurons. Pfluegers Arch 1989 ; 415 : 255-61
95. Waite JJ, Chen AD, Wardlow ML, Wiley RG, Lappi DA, Thal LJ. 192 Immunoglobulin G-saporin produces graded behavioral and biochemical changes accompanying the loss of cholinergic neurons of the basal forebrain and cerebellar purkinje cells. Neuroscience 1995 ; 65 : 463-76
96. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for micotubule assembly. Proc Natl Acad Sci USA 1975 ; 72 : 1858-62
97. White P, Hilley CR, Goodhart MJ, Carrasco LH, Keet JP, Williams IEI, Bowen DM. Neocortical cholinergic neurons in elderly people. Lancet 1977 ; 1 : 668-71
98. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 1990 ; 250 : 279-82
99. 3H]inositol 1,4,5-trisphosphate binding in Alzheimer's disease. Neurosci Lett 1988 ; 94: 198-202